Meeting
2023 ASCO Annual Meeting
Efficacy and safety of irinotecan-eluting HepaSphere transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable colorectal liver metastases.
Authors
Aiwei Feng
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital & Institute, Beijing, China
Aiwei Feng , Song Gao , Jianhai Guo , Fuxin Kou , Shaoxing Liu , Xin Zhang , Baojiang Liu , Xiaodong Wang , Hui Chen , Haifeng Xu , Peng Liu , Guang Cao , Qinzong Gao , Xu Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3585)
DOI
10.1200/JCO.2023.41.16_suppl.3585
Abstract #
3585
Poster Bd #
285
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer.
First Author: Paul Eliezer Oberstein
Poster
2021 Gastrointestinal Cancers Symposium
Inoperable stage IV colorectal cancer with intact primary tumor in patients receiving palliative chemotherapy: Does the response to chemotherapy correlate between primary and metastatic sites? An Irish cancer center experience.
First Author: Ruba Hamed
Poster
2021 Gastrointestinal Cancers Symposium
Identification of transcriptomic determinants to predict the efficacy of anti-EGFR treatment of colorectal cancer patients.
First Author: Saikat Chowdhury